Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00901615
Other study ID # R2CHOP-1
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date January 6, 2009
Est. completion date November 23, 2015

Study information

Verified date August 2018
Source Lymphoma Study Association
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to determine the recommended dose (RD) of lenalidomide (Revlimid) when administered in association with R-CHOP (rituximab (R), cyclophosphamide, doxorubicin, vincristine and prednisone).


Description:

The study is a dose escalation study of lenalidomide (Revlimid) administered orally during 14 days in combination with fixed doses of rituximab (R), cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks (R-CHOP 21) in patients with B-cell lymphoma.


Recruitment information / eligibility

Status Completed
Enrollment 108
Est. completion date November 23, 2015
Est. primary completion date November 19, 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Patients with one of the following B-cell Lymphoma, CD 20 positive:

- Mantle cell, Marginal zone, follicular

- Histological transformation from low grade to high grade

- Diffuse large B cell

- Aged from 18 to 70 years

- WHO performance status 0, 1 or 2

- Signed inform consent

- Life expectancy of = 90 days (3 months).

- Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL not more than 3 days from the start of study drug and must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control, at least 4 weeks before she starts taking lenalidomide. FCBP must also agree to monthly pregnancy testing and must be counseled at a minimum of every 4 weeks about pregnancy precautions and risks of fetal exposure.

- Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential. Men must also be counseled at a minimum of every 4 weeks about pregnancy precautions and risks of fetal exposure.

- † A female patient is considered to have childbearing potential unless she meets at least one of the following criteria 1) Age > 50 years and naturally amenorrhoeic for > 1 year (amenorrhoea following cancer therapy does not rule out childbearing potential); or 2) Premature ovarian failure confirmed by a specialist gynaecologist or 3) Previous bilateral salpingo-oophorectomy, or hysterectomy, or 4) XY genotype, turner syndrome, uterine agenesis.

Exclusion Criteria:

- Previous treatment with immunotherapy or chemotherapy except:

- Chlorambucil or Cyclophosphamide per os alone during less than 6 months, if stopped more than one year before inclusion

- Rituximab alone during less than three months, if stopped more than one year before inclusion

- Previous radiotherapy except if localized to one lymph node area

- Other type of lymphomas: Burkitt, T cell, lymphocytic, CD 20 negative

- Central nervous system or meningeal involvement

- Contraindication to any drug contained in the chemotherapy regimen

- HIV disease, active hepatitis B or C

- Any serious active disease or co-morbid medical condition (according to investigator's decision)

- Any of the following laboratory abnormalities :

- Absolute neutrophil count (ANC) < 1,500 cells/mm3 (1.5 x 109/L).

- Platelet count < 100,000/mm3 (100 x 109/L).

- Serum SGOT/AST or SGPT/ALT 5.0 x upper limit of normal (ULN).

- Serum total bilirubin > 2.0 mg/dL (34 µmol/L), except in case of hemolytic anemia.

- Calculated creatinine clearance (Cockcroft-Gault formula) of < 50 mL /min

- Prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for = 3 years

- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.

- Pregnant or lactating females.

- Prior = Grade 3 allergic reaction/hypersensitivity to thalidomide.

- Prior = Grade 3 rash or any desquamating (blistering) rash while taking thalidomide.

- Subjects with = Grade 2 neuropathy.

- Prior use of lenalidomide.

- Use of any standard or experimental anti-cancer drug therapy within 28 days of the initiation (Day 1) of study drug therapy.

Study Design


Intervention

Drug:
Lenalidomide and R-CHOP
Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.

Locations

Country Name City State
France CHU de Dijon Dijon
France CHRU Lille Lille
France CHU Lyon Sud Pierre Benite
France Centre Henri Becquerel Rouen
France CHU Brabois Vandoeuvre les Nancy

Sponsors (1)

Lead Sponsor Collaborator
Lymphoma Study Association

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Dose Limiting Toxicities 42 days
Secondary Complete response rate and Overall response rate at the end of treatment 3 months after the end of treatment
Secondary Complete and Overall response rates after induction at the end of third cycle of treatment (between Day 56 and Day 63)
Secondary Progression-Free Survival and Overall survival 7 years
Secondary Duration of response 7 years
Secondary Collection of adverse events 6 months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Recruiting NCT05976763 - Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma Phase 3
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Recruiting NCT05471843 - Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma Phase 1/Phase 2
Recruiting NCT05076097 - A Study of OLR in First-line Treatment of Mantle Cell Lymphoma Phase 2
Active, not recruiting NCT04082936 - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03891355 - Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL Phase 2
Recruiting NCT04883437 - Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Phase 2
Terminated NCT03585725 - A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma Early Phase 1
Recruiting NCT02892695 - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma Phase 1/Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT01665768 - Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma Phase 2
Completed NCT01437709 - Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant Phase 2
Completed NCT00963534 - Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. Phase 1/Phase 2
Completed NCT00921414 - Mantel Cell Lymphoma Efficacy of Rituximab Maintenance Phase 3
Withdrawn NCT00541424 - Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma N/A
Completed NCT01456351 - Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab Phase 3
Completed NCT01851551 - Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL Phase 1/Phase 2
Completed NCT03295240 - The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma Early Phase 1

External Links